Hillsborough, NJ, United States of America

Steven David Paget

USPTO Granted Patents = 18 (Patent Applications = 5)

CIPO Patents = 4

EPO Patents = 4 (Patent Applications = 1)

Average Co-Inventor Count = 5.4

ph-index = 5

Forward Citations = 55(Granted Patents)

Location History:

Belle Mead, NJ (US) (2002)
Hillborough, NJ (US) (2017)
Hillsborough, NJ (US) (2003 - 2021)

Company Filing History:

10 out of 183

Ptc Therapeutics, Inc.

patents

3 out of 2,076

Janssen Pharmaceutica Nv

patents

3 out of 363

Ortho-mcneil Pharmaceutical Corp.

patents

4. 1 out of 8

Venenum Biodesign, LLC

patents

5. 1 out of 832,680

Other

patents

Years Active: 2002-2021

Loading Chart...

18 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11180483 - Substituted reverse pyrimidine Bmi-1 inhibitors (2021-11-23),

2. 11161864 - Sting agonists (2021-11-02),

3. 10584115 - Substituted pyridine and pyrazine BMI-1 inhibitors (2020-03-10),

4. 10428050 - Substituted reverse pyrimidine Bmi-1 inhibitors (2019-10-01),

5. 10370371 - Substituted pyrimidine Bmi-1 inhibitors (2019-08-06),

6. 9975878 - Substituted triazine BMI-1 inhibitors (2018-05-22),

7. 9593108 - Compounds and methods for antiviral treatment (2017-03-14),

8. 8735414 - Indole derivatives and methods for antiviral treatment (2014-05-27),

9. 8530475 - Bridged aryl piperazines derivatives useful for the treatment of CNS, GI-urinary and reproductive disorders (2013-09-10),

10. 7973069 - Methods for treating hepatitis C (2011-07-05),

11. 7781478 - Methods for treating hepatitis C (2010-08-24),

12. 7772271 - Methods for treating hepatitis C (2010-08-10),

13. 7732612 - 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones (2010-06-08),

14. 7179805 - 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones (2007-02-20),

15. 6951863 - Pyridoarylphenly oxazolidinone antibacterials, and related compositions and methods (2005-10-04),

Title: Steven David Paget: Innovator in Cancer Treatment

Introduction

Steven David Paget is a notable inventor based in Hillsborough, NJ (US), recognized for his significant contributions to the field of cancer treatment. With a total of 18 patents to his name, Paget has developed innovative compounds that target specific proteins involved in cancer progression.

Latest Patents

Among his latest patents, Paget has introduced substituted reverse pyrimidine Bmi-1 inhibitors. These amine-substituted compounds are designed to inhibit the function of the B-cell specific Moloney murine leukemia virus integration site 1 (Bmi-1) protein. The methods described in his patent aim to reduce the level of Bmi-1 to treat cancers mediated by this protein. Additionally, he has developed Sting agonists, which are compounds effective at modulating the STING protein. These compounds can be utilized as medicaments for treating or preventing disorders influenced by STING agonism.

Career Highlights

Paget has worked with prominent companies in the pharmaceutical industry, including PTC Therapeutics, Inc. and Janssen Pharmaceutica NV. His work in these organizations has allowed him to advance his research and contribute to the development of innovative cancer therapies.

Collaborations

Throughout his career, Paget has collaborated with esteemed colleagues such as Hongyu Ren and Richard Gerald Wilde. These partnerships have played a crucial role in enhancing his research and expanding the impact of his inventions.

Conclusion

Steven David Paget's work exemplifies the spirit of innovation in the field of cancer treatment. His patents and collaborations reflect a commitment to advancing medical science and improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.